MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
Rhea-AI Summary
MAIA Biotechnology (NYSE American: MAIA) reported initial efficacy data from Part C of its Phase 2 THIO-101 expansion trial in third-line advanced non-small cell lung cancer.
Ateganosine followed by cemiplimab achieved a 90.5% disease control rate (19/21 patients) in an efficacy-evaluable, heavily pre-treated population, with an acceptable safety profile and completed international enrollment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Interim disease control rate of 90.5% (19/21) in Part C efficacy-evaluable patients
- Previously reported 88% DCR in third-line NSCLC patients in Parts A and B of THIO-101
- Disease control rate described as close to triple reported 25–35% DCR for standard chemotherapy
- All Part C patients previously treated with docetaxel and resistant to immunotherapy and other chemotherapies, yet high DCR observed
- Treatment with ateganosine followed by cemiplimab shows an acceptable safety profile to date
- International enrollment for Phase 2 THIO-101 Part C has been completed
Negative
- Interim Part C efficacy data currently based on a small efficacy-evaluable sample of 21 patients
- Results are early and described as initial, indicating longer-term efficacy and survival outcomes are not yet reported
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Phase 2 enrollment update | Positive | -2.9% | Completed international enrollment for THIO-101 Part C in third-line NSCLC. |
| Jun 18 | Site enrollment start | Positive | +3.4% | Opened enrollment at Emory’s Winship Cancer Institute for THIO-101 expansion. |
| Jun 10 | New clinical site | Positive | -2.3% | Activated second U.S. site for international THIO-101 expansion trial. |
| Jun 04 | Phase 3 trial progress | Positive | +4.9% | Reported dosing and enrollment momentum in pivotal Phase 3 THIO-104 trial. |
| Jun 01 | ASCO trial poster | Positive | -6.5% | Presented Phase 3 THIO-104 trial-in-progress poster at ASCO 2026 meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical-trial headlines have often seen share-price moves that diverged from the seemingly positive clinical and regulatory catalysts.
Historical Comparison
Over the last 5 clinical-trial updates, shares typically moved about 0.67% lower on average, despite seemingly constructive data. This efficacy-focused update fits that series of clinically positive but market-cautious reactions.
Recent same-tag history traces a steady NSCLC program build-out, from ASCO Phase 3 disclosures and trial activation through multi-country Phase 2 site expansion and full Part C enrollment, culminating in today’s first efficacy readout from the Part C cohort.
Regulatory & Risk Context
Reported short interest appears relatively low, suggesting limited short-squeeze fuel but also moderating the risk of extreme volatility driven purely by short covering.
Key Terms
disease control rate medical
non-small cell lung cancer medical
standard-of-care medical
telomere targeting medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population
CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC).
Initial data from the THIO-101 Part C 3L studies1 show a disease control rate (DCR) of
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an
MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable safety profile to date in a heavily pre-treated population.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-101 Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com
1 As of July 06, 2026
2 Matsumoto H, et al. Transl Lung Cancer Res 2021;10:2278–89
